Spironolactone Misses the Mark in Acute MI Without HF
Med Page Today
NOVEMBER 17, 2024
(MedPage Today) -- CHICAGO -- A mineralocorticoid receptor antagonist (MRA) was unable to further improve 3-year outcomes of acute myocardial infarction (MI) in the modern era, based on the CLEAR OASIS 9 trial. Among heart attack survivors without.
Let's personalize your content